Gummy smile (GS) is an aesthetic issue characterized by excessive visibility of the gingiva when smiling. The etiology of this condition is multifactorial and can include skeletal, dental, soft tissue, and periodontal factors. The treatment for GS depends on the cause and severity of the condition. Surgical treatments involve procedures such as orthognathic surgery, gingivectomy, gingivoplasty, and lip repositioning with or without myotomy. These treatments provide permanent results but require an invasive approach that includes hospitalization, significant pain, potential risks, and a longer recovery period, which prevents a quick return to everyday life. The outcomes are often incomplete. One of the non-invasive methods is orthodontic therapy, which can achieve long-term results, but it is expensive, requires a longer to complete, and is not indicated for all patients with GS. Due to these factors, minimally invasive techniques, primarily the application of botulinum toxin type A (BTA), are increasingly being used. The literature also describes the use of hyaluronic acid-based fillers and autologous fat tissue for GS correction. The advantages of treating GS with BTA injections include a minimally invasive procedure and effects that are visible just a few days after treatment, with very rare side effects or complications. Optimal candidates for this procedure typically have mild to moderate GS caused by a hyperactive upper lip, while in other etiological cases, BTA may be used as an additional therapeutic measure. Knowledge of the anatomy of the perioral muscles allows for adequate diagnosis and localization of injection sites, which reduces the risk of unwanted occurrences. BTA works by preventing the transmission of signals from nerve endings to the muscles. In this way, it reduces the activity of the upper lip elevator muscle, changes its position when smiling, and decreases gingival visibility. The main drawback is the temporary effect, which necessitates regular treatments to maintain results.